Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of ... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 3 | 8.30105146652 | 36.14 | 39.9 | 35.26 | 95258 | 37.73405 | DR |
| 4 | 4.06 | 11.5735461802 | 35.08 | 39.9 | 31.68 | 86023 | 36.06851481 | DR |
| 12 | 9.26 | 30.9906291834 | 29.88 | 57.14 | 29.88 | 81523 | 38.43033385 | DR |
| 26 | 19.07 | 95.0174389636 | 20.07 | 57.14 | 19.61 | 63411 | 34.82921467 | DR |
| 52 | 34.07 | 671.992110454 | 5.07 | 57.14 | 4.72 | 60890 | 27.19256517 | DR |
| 156 | 34.14 | 682.8 | 5 | 57.14 | 2.76 | 37670 | 17.66006779 | DR |
| 260 | 24.48 | 166.984993179 | 14.66 | 57.14 | 1.75 | 58991 | 10.7946792 | DR |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。